Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALStandard

NEO-SYNALAR

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

Standard Dose
0.025%;EQ 3.5MG BASE/GM
Max Dose
Refer to approved labeling
Primary Use
Review priority: UNKNOWN Marketing status: Prescription
Summary

Approval overview NEO-SYNALAR is listed in Drugs@FDA under application 060700 (ANDA).

Review priority: UNKNOWN Marketing status: Prescription Active ingredient FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE Form and strength CREAM;TOPICAL - 0.025%;EQ 3.5MG BASE/GM Sponsor EUROFARMA Submission history Latest submission status date: 2015-02-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview NEO-SYNALAR is listed in Drugs@FDA under application 060700 (ANDA). Review priority: UNKNOWN Marketing status: Prescription Active ingredient FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE Form and strength CREAM;TOPICAL - 0.025%;EQ 3.5MG BASE/GM Sponsor EUROFARMA Submission history Latest submission status date: 2015-02-25 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: UNKNOWN

Interaction Notes

  • No interaction notes stored yet.
NEO-SYNALAR (FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE) | Drug Monograph | MedicHelpline